Phase I dose-expansion data in relapsed or refractory small-cell lung cancer point to a role for biomarker analytics alongside treatment with AZD2811. The work, led by Johnson, Fabbri, Ciardullo and colleagues, uses biomarker analysis to track treatment efficacy signals as the program expands in early clinical testing. For drug developers, the study’s emphasis is on building response monitoring into early-stage oncology development rather than treating biomarker work as a post-hoc exercise. In SCLC—where patient heterogeneity and rapid disease dynamics complicate assessment—embedding biomarker tracking can help tighten go/no-go decisions as dose and schedule questions are resolved. While the excerpt does not include response rates or specific biomarker endpoints, the clear clinical-development angle is that biomarker analysis is being used as an active readout during expansion, supporting iterative optimization of AZD2811’s development path.